ClinicalTrials.gg
Enrolling by invitationNCT07225231TETRISUpdated Oct 8, 2026

Clinical Utility of Reduced EEG Home Monitoring in Fenfluramine Titration for Dravet and LGS

An interventional study of Byteflies Remote patient monitoring solution (with reduced EEG) in Dravet Syndrome (DS) and Lennox Gastaut Syndrome (LGS), sponsored by Byteflies. Enrolling by invitation at 3 sites in United States. Open to participants aged 3 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Byteflies · Not applicable, Interventional, and Supportive care

How we know

Updated Oct 8, 2026Now Enrolling by invitationFirst site in United States+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
3 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 61 studies in Epilepsies, Myoclonic with a site in United States — 11 open to participants now, 17 under way, 4 of them phase 3. Epilepsies, Myoclonic · United States.

Planned enrollment
32nd of 43
20 · median 36
Started
2026
with 3 others
No phase
2 of 61
1 open now
Primary completion
2027-12
later than 12 of 16 live
Registered
59th of 61
by date

Among the 61 studies in Epilepsies, Myoclonic with a site in United States, this one is the 32nd largest by planned enrollment of the 43 interventional ones that give a count, is one of 4 that started in 2026, is one of 2 with no phase, reaches primary completion later than 12 of the 16 other live ones, and was the 59th registered.

Epilepsies, Myoclonic

92 studies on the registry are indexed under Epilepsies, Myoclonic; 21 are open to participants now.

Browse Epilepsies, Myoclonic studies →

Open to participants now

11 of the 61 studies in Epilepsies, Myoclonic with a site in United States are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 14 Epilepsies, Myoclonic studies recruiting now, 3 (21%) set no upper age limit and 10 (71%) stop at 75 or younger; 11 take children under 18; 3 take healthy volunteers.

This study: 3 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 61 studies in Epilepsies, Myoclonic with a site in United States, or all of them as a file.
02

Study summary

The goal of this real world data study is to evaluate the clinical utility of remote patient monitoring solution (using Byteflies' EpiCare@Home with reduced EEG montage and other vital signs) with Dravet and LGS patients (ages 3 and up with the exclusion of adults above weight allowing variable titration) to identify an optimal Fenfluramine treatment.

Patients will wear one or more small portable and medically certified measuring devices. Through these devices, electroencephalography (EEG) signals, as well as electro-cardiography (ECG), heart rate, respiration rate, and physical activity are measured, which allows the patient's physician to detect potential seizures, and thus gain more insights.

Participants will be asked to wear the devices three times at home for remote monitoring periods lasting between 3 and 7 consecutive days. The duration of each monitoring period will be determined by the physician based on the type of epilepsy and the frequency of seizures.

03

Conditions studied

  • Dravet Syndrome (DS)
  • Lennox Gastaut Syndrome (LGS)
04

Who can participate

Ages eligible
3 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Patients with a confirmed Dravet syndrome or Lennox-Gastaut syndrome diagnosis who are eligible for Fenfluramine.
  • Patients for which the neurologist decided to prescribe Fenfluramine as a relevant treatment approach and who have not been prescribed Fenfluramine before.
  • Patients or caregivers should be able and willing to maintain a seizure diary e.g. using a digital seizure diary.

Exclusion Criteria: Patients who

  • Have been diagnosed with or are suspected to have life-threatening conditions that could result in immediate danger;
  • Need to undergo an MRI scan or cardiac defibrillation;
  • Have an active implanted device such as a pacemaker, defibrillator, or vagal nerve, or brain stimulator;
  • Are unable to provide written , either directly or via a legal guardian.
  • Have known allergy or skin-sensitivity to the materials used in the Byteflies Adhesives
  • Are between 0 and 3 years of age;
  • Are above weight allowing variable titration
  • The patient is on any medication that would be for use with Fenfluramine at the execution of the study eg. LP352 (bexicaserin), loracaserin, monoamine-oxidase inhibitors, SSRIs, SNRIs, tricyclic antidepressants or other serotonergic agonists or antagonists (antipsychotics).
  • Have a prescribed concomitant use of Stiripentol
  • Have any other condition or finding that would compromise the safety of the participant or the quality of the data, or otherwise interfere with achieving the objectives.
  • A history of cardiovascular or cerebrovascular disease, aortic or mitral valve regurgitation diagnosed by echography
  • Patients/caregivers who have only reported/detected non-motor seizures
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Patient treated with standard-of-care fenfluramine and wearing remote patient monitoring solution

    Participants will receive standard-of-care fenfluramine treatment as prescribed for their clinical condition. In addition, they will be equipped with a remote patient monitoring (RPM) solution designed to collect EEG, ECG and EMG data.

    Device: Byteflies Remote patient monitoring solution (with reduced EEG)

Interventions

  • DeviceByteflies Remote patient monitoring solution (with reduced EEG)

    Remote patient monitoring (RPM) solution designed to collect EEG, ECG and EMG data.

06

What researchers measure

Primary outcomes

  1. Physician confidence in treatment decision-making using RPM data

    The primary endpoint of the study is defined as the proportion of cases in which physicians report higher confidence in treatment decision-making when using RPM-enhanced data compared to standard care, with increased confidence defined as an RPM confidence score greater than the standard confidence score. The primary endpoint is considered successful if physicians demonstrate improved confidence in their treatment decisions for at least 50% of the patients when RPM data is available. For each patient, the following assessments will be performed: 1. Standard Decision (-RPM): Clinicians will determine the treatment plan based on routine data. Clinicians will record their confidence in this decision on a 1-5 Likert scale (1 = not confident, 5 = very confident). 2. RPM-Enhanced Decision (+RPM): Clinicians will determine the treatment plan using the same routine data plus information provided by the RPM system. Clinicians will record their confidence in this decision on a 1-5 Likert scale.

    Time frame: At end of first RPM period (2 weeks after treatment start), at end of second RPM period (between 1 to 3 months after treatment start), at end of third RPM period (between 3 to 9 months after treatment start)

07

Study locations

3 sites
  • Norton Children's Research Institute - University of Louisville School of Medicine
    Louisville, Kentucky 40202, United States
  • Child Neurology & Consultants of Austin
    Austin, Texas 78749, United States
  • MultiCare Mary Bridge Children's Hospital and Health System
    Tacoma, Washington 98405, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Apr 2026 (actual). Primary completion is estimated for Dec 2027, 20 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 8, 2026: start Dec 2025 → Apr 2026, primary completion Dec 2026 → Dec 2027 and completion Dec 2026 → Feb 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2025
First posted
Nov 6, 2025
StartActual
Apr 20, 2026was Dec 2025
Primary completionEst.
Dec 28, 2027was Dec 2026
CompletionEst.
Feb 28, 2028was Dec 2026
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Enrolling by invitation
changed Oct 8, 2026
Sites
3 sites added — first site in United States
Show 3 added (3 United States)
  • Norton Children's Research Institute - University of Louisville School of Medicine · Louisville, United States
  • Child Neurology & Consultants of Austin · Austin, United States
  • MultiCare Mary Bridge Children's Hospital and Health System · Tacoma, United States
Oct 8, 2026
Start date
Dec 15, 2025→Apr 20, 2026 (actual)
Oct 8, 2026
Primary completion
Dec 31, 2026→Dec 28, 2027
Oct 8, 2026
Study completion
Dec 31, 2026→Feb 28, 2028
Oct 8, 2026
Contact
No study contact listed any more: removed n•••@byteflies.com · •••1323
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    Not yet recruiting→Enrolling by invitation
    3 sites added — first site in United States
    Show 3 added (3 United States)
    • Norton Children's Research Institute - University of Louisville School of Medicine · Louisville, United States
    • Child Neurology & Consultants of Austin · Austin, United States
    • MultiCare Mary Bridge Children's Hospital and Health System · Tacoma, United States
    Start date Dec 15, 2025→Apr 20, 2026 (now actual)
    Primary completion Dec 31, 2026→Dec 28, 2027
    Study completion Dec 31, 2026→Feb 28, 2028
    Contact No study contact listed any more: removed n•••@byteflies.com · •••1323
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07225231
Lead sponsor
Byteflies
Collaborators
UCB Pharma
Responsible party
Sponsor
First posted
Nov 6, 2025
Start date
Apr 20, 2026
Primary completion
Dec 28, 2027 (estimated)
Completion
Feb 28, 2028 (estimated)
Last update
Oct 8, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion